FSD Pharma Inc. HUGE FSDDF said Monday it has obtained approval for its Class B subordinate shares to list on the Nasdaq Capital Market.
The company hasn’t provided a specific date for when the stock will begin trading on the Nasdaq.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
FSD Pharma is a specialty biotech pharmaceutical research and development company oriented toward creating a variety of synthetic compounds addressing the human endocannabinoid system to help treat various central nervous system illnesses and autoimmune disorders.
During the second quarter of 2019, FSD Pharma purchased Prismic Pharmaceuticals.
FSD Pharma shares were trading 18.1% higher at $5.35 at the time of publication Monday.
Related Links:
Cannabis Earnings Roundup: 4Front, WeedMD, FSD Pharma, 1933 Industries, True Leaf
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
